-
Letters were sent to healthcare professionals about Jext adrenaline autoinjectors, rivaroxaban, Ozurdex 700 micrograms intravitreal implant, sildenafil, hydrochlorothiazide, and Epilim Chronosphere (sodium valproate). We als鈥�
-
An alert was recently issued by MHRA about CoaguChek Test Strips for Point of Care and Home Use due to a risk of false high results. Affected CoaguChek test strips may give false high results for INR values above 4.5 when co鈥�
-
Valproate medicines must not be used in women of childbearing potential unless the Pregnancy Prevention Programme is in place. If you are involved in the care of female patients on valproate in the UK, see a reminder of acti鈥�
-
Letters were sent about daclizumab beta (Zinbryta鈻�), alteplase (Actilyse), Esmya (ulipristal acetate), and Xofigo鈻� (radium-223-dichloride). MHRA issued alerts and recalls for batches of Nutriflex Omega Special 2500 ml and Nu鈥�
-
More than one treatment course is authorised only in women who are not eligible for surgery, and liver function monitoring is to be carried out in all women treated with Esmya. Before initiation, discuss with women the rare 鈥�
-
Letters were sent about valproate medicines, atezolizumab (Tecentriq鈻�), and nusinersen (Spinraza鈻�). MHRA issued alerts and recalls for valsartan-containing medicines, Fiasp FlexTouch pre-filled pens, melatonin capsules, and 鈥�
-
New pharmacokinetic data show mean exposure of darunavir (brand name Prezista) boosted with cobicistat (available in combination in Rezolsta鈻�, Symtuza鈻�) to be lower during the second and third trimesters of pregnancy than du鈥�
-
Report to the Yellow Card Scheme suspected adverse reactions associated with medicines taken during pregnancy experienced by women or the baby or child. Obstetricians and midwives have a particularly important role in provid鈥�
-
Letters were sent about Cetrotide (cetrorelix acetate), Eperzan鈻�(albiglutide), darunavir/cobicistat, Keytruda鈻� (pembrolizumab), Denzapine (clozapine) 50 mg/mL oral suspension, and Bleo-Kyowa (bleomycin sulphate).
-
New safety recommendations have been issued while an EU review evaluates cases of neural tube defects in babies born to mothers who became pregnant while taking the HIV medicine dolutegravir.
-
Letters were sent about azithromycin, Lynparza鈻�(Olaparib), Xgeva鈻� (denosumab), Lymphoseek (tilmanocept), ReoPro (abciximab) and dolutegravir; you still have time to complete a quick survey to tell us your views on the way me鈥�
-
Use materials online now and hardcopies arriving over the coming weeks by post to ensure women and girls of childbearing potential on valproate medicines meet the requirements of the Pregnancy Prevention Programme.
-
Valproate medicines must no longer be used in women or girls of childbearing potential unless a Pregnancy Prevention Programme is in place. Ensure all women and girls (and their parent, caregiver, or responsible person, if n鈥�
-
An alert was issued about T34 ambulatory syringe pumps.
-
Temporary safety measures are in place while an EU review investigates the link between cases of serious liver injury, including 4 cases requiring liver transplantation, and Esmya for uterine fibroids.
-
Letters were sent about ellaOne, ERWINASE, Eperzan鈻�, Ocaliva鈻�, Velcade, Esmya, and Bleo-Kyowa.
-
Monitor patients closely and remove the vaginal delivery system immediately in cases of excessive or prolonged uterine contractions, at the onset of labour, or if there is clinical concern for mother or baby.
-
Mycophenolate mofetil and its active metabolite mycophenolic acid, both used to prevent transplant rejection, are teratogenic and genotoxic. The available clinical evidence does not indicate an increased risk of malformation鈥�
-
Letters were sent about Buccolam (midazolam), misoprostol vaginal delivery system (Mysodelle), noradrenaline, Relenza (zanamivir), mycophenolate mofetil/mycophenolic acid, Flolan, and Fludara.
-
Alerts were recently issued about BD Alaris/Asena syringe pumps and Maxter Catheters nasogastric (NG) feeding tubes.
-
A summary of letters sent to healthcare professionals, including an important reminder about the withdrawal of retigabine (Trobalt) from the market.
-
Babies born to mothers who take valproate medicines (Epilim鈻�, Depakote鈻�) during pregnancy have a 30鈥�40% risk of developmental disability and a 10% risk of birth defects. Despite communications to prescribers in January 2015 鈥�
-
A summary of letters sent to relevant healthcare professionals in January 2017.
-
A summary of letters sent to healthcare professionals in September 2016, including important information for professionals who specialise in epilepsy treatment regarding the withdrawal from the market of retigabine (Trobalt).
-
Medicines or herbal remedies that induce CYP3A4 enzymes reduce blood levels of levonorgestrel, which may reduce emergency contraceptive efficacy.
-
There have been rare reports of Nexplanon implants having reached the lung via the pulmonary artery. An implant that cannot be palpated at its insertion site in the arm should be located as soon as possible and removed at th鈥�
-
In May 2016, letters were sent regarding Nexplanon (etonogestrel implant) and ERWINASE.
-
In February 2016, a letter was sent to healthcare professionals regarding medicines containing valproate.
-
Children exposed to valproate in utero are at high risk of developmental disorders and congenital malformations. Use the new communication materials below to discuss these risks with patients
-
Levonorgestrel-releasing intrauterine systems should always be prescribed by brand name because products have different indications, durations of use, and introducers.
-
Mycophenolate mofetil and its active metabolite mycophenolic acid are associated with a high rate of serious birth defects and increased risk of spontaneous abortion.
-
In November, letters were sent regarding thalidomide, mycophenolate mofetil, nicorandil, InductOs, and dimethyl fumarate
-
Mirabegron is now contraindicated in patients with severe uncontrolled hypertension; advice about regular monitoring is being introduced because of cases of severe hypertension.
-
A letter was sent to healthcare professionals about mirabegron for symptomatic treatment of urgency, increased
micturition frequency, or urgency incontinence.
-
Patient reminder cards about the risk of osteonecrosis of the jaw are being introduced; denosumab 120 mg is now contraindicated in patients with unhealed lesions from dental or oral surgery.
-
EU review confirms that the cardiovascular risk of high-dose ibuprofen (鈮�2400mg/day) is similar to COX 2 inhibitors and diclofenac.
-
The most important risk factors for uterine perforation are insertion during lactation and insertion in the 36 weeks after giving birth. Before inserting an IUS or IUD, inform women of the risk and the symptoms of perforatio鈥�
-
The licence-holder of ferumoxytol has voluntarily withdrawn it from the UK market for commercial reasons.
-
The new module helps clinicians understand how to identify, manage and avoid side effects when using corticosteroids.
-
Since November 2014, letters were sent regarding vismodegib (Erivedge 鈻�), chlorhexidine solutions, carbocisteine oral liquid (Mucodyne Paediatric 125mg/5ml), regadenoson (Rapiscan), a parenteral nutrition emulsion (Triomel),鈥�
-
Children exposed in utero to valproate are at a high risk of serious developmental disorders (in up to 30-40% of cases) and/or congenital malformations (in approximately 10% of cases).
-
Minimising the risk of osteonecrosis of the jaw; monitoring for hypocalcaemia.
-
New recommendations are being introduced to minimise the risk of serious hypersensitivity reactions with ferumoxytol.
-
Emergency contraceptives remain suitable for all women regardless of the woman鈥檚 weight or body mass index (BMI).
-
Reporting suspected adverse reactions experienced by the woman or child associated with medicines taken during pregnancy.
-
Non-hormonal or progestogen-only contraception should be considered in some situations.
-
St John鈥檚 wort interacts with hormonal contraceptives reducing the effectiveness and increasing the risk of unplanned pregnancy.
-
A review of the latest evidence on the risk of thromboembolism advises to consider risk factors and remain vigilant for signs and symptoms.
- the risk of blood clots with all low-dose CHCs is small
- there is good evid鈥�
-
Not for use in pregnancy unless there is no effective alternative.
-
Use has been restricted to 48 hours鈥� maximum parenteral use under specialist supervision, after a European safety review.